Search details
1.
Preemptive treatment of de novo donor-specific antibodies in lung transplant patients reduces subsequent risk of chronic lung allograft dysfunction or death.
Am J Transplant
; 23(4): 559-564, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36732088
2.
Does 1-minute walk test predict results of 6-minute walk test in patients with idiopathic pulmonary fibrosis?
Sarcoidosis Vasc Diffuse Lung Dis
; 38(1): e2021005, 2021.
Article
in English
| MEDLINE | ID: mdl-33867792
3.
Use of donor-derived-cell-free DNA as a marker of early allograft injury in primary graft dysfunction (PGD) to predict the risk of chronic lung allograft dysfunction (CLAD).
J Heart Lung Transplant
; 40(6): 488-493, 2021 06.
Article
in English
| MEDLINE | ID: mdl-33814284
4.
Donor-derived cell-free DNA accurately detects acute rejection in lung transplant patients, a multicenter cohort study.
J Heart Lung Transplant
; 40(8): 822-830, 2021 08.
Article
in English
| MEDLINE | ID: mdl-34130911
5.
Donor-derived cell-free DNA predicts allograft failure and mortality after lung transplantation.
EBioMedicine
; 40: 541-553, 2019 Feb.
Article
in English
| MEDLINE | ID: mdl-30692045
6.
Late manifestation of alloantibody-associated injury and clinical pulmonary antibody-mediated rejection: Evidence from cell-free DNA analysis.
J Heart Lung Transplant
; 37(7): 925-932, 2018 07.
Article
in English
| MEDLINE | ID: mdl-29500138
7.
When is cystic fibrosis not cystic fibrosis? The importance of appropriately classifying patients.
Respir Med
; 193: 106727, 2022 03.
Article
in English
| MEDLINE | ID: mdl-35114577
Results
1 -
7
de 7
1
Next >
>>